ID   RMS-YM
AC   CVCL_A792
SY   RMSYM
DR   CLO; CLO_0050151
DR   BioSample; SAMN03472121
DR   Cosmic; 687962
DR   DepMap; ACH-002048
DR   GEO; GSM219743
DR   RCB; RCB1695
DR   Wikidata; Q54950693
RX   PubMed=1906291;
RX   PubMed=19235922;
RX   PubMed=23828214;
RX   PubMed=23882450;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~30 hours (PubMed=1906291).
CC   Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Arg1163Ter (c.3487C>T); ClinVar=VCV000954289; Zygosity=Homozygous (DepMap=ACH-002048).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urachus; UBERON=UBERON_0002068.
ST   Source(s): RCB=RCB1695
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 10,11
ST   D16S539: 11
ST   D5S818: 12,14
ST   D7S820: 10,11
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 18
//
RX   PubMed=1906291; DOI=10.1038/bjc.1991.193;
RA   Kubo K., Naoe T., Utsumi K.R., Ishiguro Y., Ueda K., Shiku H.,
RA   Yamada K.;
RT   "Cytogenetic and cellular characteristics of a human embryonal
RT   rhabdomyosarcoma cell line, RMS-YM.";
RL   Br. J. Cancer 63:879-884(1991).
//
RX   PubMed=19235922; DOI=10.1002/gcc.20655;
RA   Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C.,
RA   Koster J., Summersgill B.M., Messahel B., Versteeg R.,
RA   Pritchard-Jones K., Kool M., Shipley J.M.;
RT   "Genomic imbalances in rhabdomyosarcoma cell lines affect expression
RT   of genes frequently altered in primary tumors: an approach to identify
RT   candidate genes involved in tumor development.";
RL   Genes Chromosomes Cancer 48:455-467(2009).
//
RX   PubMed=23828214; DOI=10.3892/or.2013.2588;
RA   Yamamoto Y., Fukuda K., Fuchimoto Y., Matsuzaki Y., Saikawa Y.,
RA   Kitagawa Y., Morikawa Y., Kuroda T.;
RT   "Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with
RT   EGFR amplification in vitro.";
RL   Oncol. Rep. 30:1081-1086(2013).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//